New hope for PBC patients: phase 3 trial targets liver enzyme levels
NCT ID NCT07424677
First seen Feb 26, 2026 · Last updated May 01, 2026 · Updated 6 times
Summary
This study tests a drug called saroglitazar magnesium in people with primary biliary cholangitis (PBC) who either didn't respond well to or couldn't tolerate the standard treatment, ursodeoxycholic acid. The goal is to see if the drug can lower a key liver enzyme (alkaline phosphatase) to normal levels. About 89 adults aged 18 to 80 will participate in this double-blind, placebo-controlled trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY BILIARY CHOLANGITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.